In a trial in 248 HIV-1 infected adults with estimated creatinine clearance greater than 30 mL per minute but less than 70 mL per minute, 95% (235/248) of the combined population of treatment-nave subjects began on FTC+TAF with EVG+COBI (N=6) and those previously virologically-suppressed on other regimens and switched to FTC+TAF with EVG+COBI (N=242) had HIV-1 RNA less than 50 copies per mL at Week 24. Descovy (emtricitabine and tenofovir alafenamide) is a fixed dose combination tablet containing emtricitabine (FTC) and tenofovir alafenamide (TAF) for oral administration. FTC, a synthetic nucleoside analog of cytidine, is an HIV nucleoside analog reverse transcriptase inhibitor (HIV NRTI). The 120 mg/15 mg tablets are film-coated with a coating material containing polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc. No clinically significant drug interactions have been either observed or are expected when Descovy is combined with the following drugs: buprenorphine, itraconazole, ketoconazole, lorazepam, methadone, midazolam, naloxone, norbuprenorphine, norgestimate/ethinyl estradiol, and sertraline. Safety and effectiveness of Descovy for HIV-1 PrEP in pediatric patients weighing less than 35 kg have not been established. Patient . Inform uninfected individuals about and support their efforts in reducing sexual risk behavior. BMD declines of 7% or greater at the femoral neck were experienced by 1% of FTC+TAF with EVG+COBI subjects. With the exception of a decrease in the mean CD4+ cell count observed in cohort 2, the safety of this combination was similar to that in adults. Tell your healthcare provider if you become pregnant during treatment with Descovy. Do not take Descovy for HIV-1 PrEP unless you are confirmed to be HIV-1 negative. Read this Medication Guide before you start taking Descovy and each time you get a refill. Truvada vs Descovy: How do they compare for HIV and PrEP? Tenofovir Alafenamide: TAF was administered orally to pregnant rats (25, 100, or 250 mg/kg/day) and rabbits (10, 30, or 100 mg/kg/day) through organogenesis (on gestation days 6 through 17, and 7 through 20, respectively). For people taking Descovy for HIV-1 PrEP: you do not know your HIV-1 infection status. The recommended dosage of Descovy in pediatric patients weighing at least 14 kg to 35 kg is based on body weight and provided in Table 1. Serious adverse events were reported in 53% of subjects and the most common serious adverse events were pneumonia (13%), fluid overload (7%), hyperkalemia (7%) and osteomyelitis (7%). Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F) (see USP Controlled Room Temperature). You must stay HIV-1 negative to keep taking Descovy for HIV-1 PrEP. Descovy's manufacturer hasn't stated whether the tablets can be chewed, split, or crushed. The following adverse reactions are discussed in other sections of the labeling: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug (or a drug given in various combinations with other concomitant therapy) cannot be directly compared to rates in the clinical trials of another drug (or drug given in the same or different combination therapy) and may not reflect the rates observed in practice. In rats, the study was negative for carcinogenic findings. FTC+TAF with EVG+COBI was permanently discontinued due to worsening renal function in two of 80 (3%) subjects. Your healthcare provider will determine which other HIV-1 medicines may be used with Descovy. In this trial, the mean (SD) change from baseline to Week 24 in CD4+ cell count was 126 (264) cells per mm3 and the mean (SD) change in CD4% from baseline to Week 24 was 0.2% (4.4%). In a case-control substudy of intracellular drug levels and estimated number of daily doses as measured by dried blood spot testing, median intracellular tenofovir diphosphate concentrations were substantially lower in participants infected with HIV-1 at the time of diagnosis compared with uninfected matched control participants. There were no effects on fertility, mating performance, or early embryonic development when TAF was administered to male rats at a dose equivalent to 62 times (25 mg TAF) the human dose based on body surface area comparisons for 28 days prior to mating and to female rats for 14 days prior to mating through Day 7 of gestation. Drug class: Antiviral combinations. It is not known if TAF is present in animal milk. If you have trouble swallowing Descovy tablets, talk with your doctor or pharmacist. Prior to or when initiating Descovy, and during use of Descovy on a clinically appropriate schedule, assess serum creatinine, estimated . Emtricitabine: FTC, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. In this treatment group, 0.9% of subjects discontinued FTC+TAF with EVG+COBI due to adverse events during the 48-week treatment period [see Clinical Studies (14.2)]. ALERT: Find out about medicines that 120 mg/15 mg tablets: 120 mg of FTC and 15 mg of TAF (equivalent to 16.8 mg of tenofovir alafenamide fumarate). A single dose of 125 mg TAF (5 times the TAF dose in 200/25 mg Descovy) was administered to 48 healthy subjects; no serious adverse reactions were reported. In cohort 1, the virologic response rate (i.e., HIV-1 RNA less than 50 copies per mL) was 92% (46/50) and the mean increase from baseline in CD4+ cell count was 224 cells per mm3 at Week 48. Absorption, Distribution, Metabolism, and Excretion. They may want to do more tests to be sure you are still HIV-1 negative. Overall 5% of subjects permanently discontinued treatment due to an adverse event. One subject had significant (at least 4%) lumbar spine BMD loss at Week 48. Know your HIV-1 status and the HIV-1 status of your partners. Tenofovir was excreted into the milk of lactating monkeys following a single subcutaneous (30 mg/kg) dose of tenofovir at concentrations up to approximately 4% of plasma concentration, resulting in exposure (AUC) of approximately 20% of plasma exposure. Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. HBV-uninfected individuals should be offered vaccination. The safety profile of Descovy for HIV-1 PrEP was comparable to that observed in clinical trials of HIV-infected subjects based on a double-blind, randomized, active-controlled trial (DISCOVER) in which a total of 5,387 HIV-1 uninfected adult men and transgender women who have sex with men received Descovy (N=2,694) or TRUVADA (N=2,693) once daily for HIV-1 PrEP [see Clinical Studies (14.3)]. TAF, a component of Descovy, is a substrate of P-gp, BCRP, OATP1B1, and OATP1B3. For specific dosing recommendations for coadministered antiretroviral drugs, refer to their respective prescribing information [see Drug Interactions (7)]. Descovy is a two-drug fixed dose combination product containing emtricitabine (FTC) and tenofovir alafenamide (TAF). Take Descovy 1 time each day with or without food. Based on drug interaction studies conducted with the components of Descovy, no clinically significant drug interactions have been either observed or are expected when Descovy is combined with the following antiretroviral agents: atazanavir with ritonavir or cobicistat, darunavir with ritonavir or cobicistat, dolutegravir, efavirenz, ledipasvir, lopinavir/ritonavir, maraviroc, nevirapine, raltegravir, rilpivirine, and sofosbuvir. Population pharmacokinetics analysis of HIV-infected subjects in Phase 2 and Phase 3 trials of FTC+TAF and EVG+COBI showed that age did not have a clinically relevant effect on exposures of TAF up to 75 years of age [see Use in Specific Populations (8.5)]. If you do become HIV-1 positive, you need more medicine than Descovy alone to treat HIV-1. Missing doses increases your risk of getting HIV-1 infection. Get tested for HIV-1 at least every 3 months or when your healthcare provider tells you. It helps lower the chances of getting HIV through sex. Do not cover ALERT box with pharmacy label. Approved as a pharmacy medicine, Sanofi will launch Cialis Together in the second half of the year. Tenofovir Alafenamide (TAF): Limited clinical experience is available at doses higher than the recommended dose of TAF. In cohort 2, 98% (51/52) of subjects remained virologically suppressed at Week 48. in children who weigh at least 31 pounds (14 kg) and less than 77 pounds (35 kg) together with certain other HIV-1 medicines. Among the subjects in cohort 1 receiving FTC+TAF with EVG+COBI, mean BMD increased from baseline to Week 48, +4.2% at the lumbar spine and +1.3% for the total body less head (TBLH). Descovy is a newer medication that's safer for the kidneys and bone health, but it hasn't been studied in people at risk for HIV from receptive vaginal sex or injection drug use. In a 48-week trial in virologically-suppressed TDF-treated adults who switched to FTC+TAF with EVG+COBI (N=959) with a mean baseline eGFR of 112 mL per minute, mean serum creatinine was similar to baseline at Week 48; median UPCR was 61 mg per gram at baseline and 46 mg per gram at Week 48. This is not a complete list of side effects and others may occur. Common Descovy side effects may include: headache, dizziness, feeling depressed or tired; trouble sleeping, strange dreams; nausea, stomach pain; weight loss; or. Based on limited data, FTC has been shown to be present in human breast milk; it is not known if TAF is present in human breast milk. Instruct mothers with HIV-1 infection not to breastfeed because of the risk of passing the HIV-1 virus to the baby [see Use in Specific Populations (8.2)]. Generic name: emtricitabine and tenofovir alafenamide fumarate 19.79. Helps you get and maintain an erection when you need it. Manufacturer Information. Reduced susceptibility to FTC was associated with M184V or I substitutions in HIV-1 RT. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Adverse Reactions in Clinical Trials of FTC+TAF with Elvitegravir (EVG) plus Cobicistat (COBI) in Treatment-Nave Adults with HIV-1 Infection. . The estimated background rate of miscarriage in the clinically recognized pregnancies in the U.S. general population is 1520%. Mean changes from baseline BMD Z-scores were 0.07 for lumbar spine and 0.20 for TBLH at Week 48. The safety and efficacy of FTC+TAF with EVG+COBI in subjects 6 to 12 years of age weighing at least 25 kg was similar to that in antiretroviral treatment-nave adults and adolescents on this regimen, with the exception of a decrease from baseline in CD4+ cell count [see Adverse Reactions (6.1), Clinical Pharmacology (12.3) and Clinical Studies (14.2)]. ALERT: Find out about medicines that See updated prices. Severe Acute Exacerbations of Hepatitis B, Lactic Acidosis/Severe Hepatomegaly with Steatosis. If you have flu-like symptoms, you could have recently become infected with HIV-1. Adverse Reactions in a Clinical Trial of FTC+TAF with EVG+COBI in Virologically-Suppressed Adults with End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis. In 799 virologically-suppressed TDF-treated adult subjects that switched to FTC+TAF with EVG+COBI, at Week 48 mean BMD increased (1.86% lumbar spine, 1.95% total hip). Write a review. Use of Descovy in pediatric patients between 2 to less than 6 years of age and weighing at least 14 to less than 25 kg is supported by adequate and well controlled studies of FTC+TAF with EVG+COBI in adults and by a separate open-label trial of FTC+TAF with bictegravir in virologically-suppressed pediatric patients at least 2 years of age and weighing at least 14 to less than 25 kg through Week 24 (N=22; cohort 3). Too much lactic acid in your blood (lactic acidosis). Table 6 provides a listing of established or potentially clinically significant drug interactions with recommended steps to prevent or manage the drug interaction (the table is not all inclusive). Your healthcare provider will test you for HBV infection before or when you start treatment with Descovy. In a trial in 55 HIV-1 infected virologically-suppressed adults with ESRD (estimated creatinine clearance of less than 15 mL per minute) receiving chronic hemodialysis for at least 6 months who switched to FTC+TAF with EVG+COBI, 82% (45/55) maintained HIV-1 RNA less than 50 copies per mL at Week 48. 4 UNI | 4.95 per 1UNI. 2022 Gilead Sciences, Inc. All rights reserved. If you are taking Descovy for HIV-1 PrEP, missing doses increases your risk of getting HIV-1 infection. Descovy. A "flare-up" is when your HBV infection suddenly returns in a worse way than before. Hepatitis B and/or Hepatitis C Virus Infection. The effects of higher doses are unknown. Since TAF is rapidly converted to tenofovir and a lower tenofovir exposure in rats and mice was observed after TAF administration compared to TDF administration, carcinogenicity studies were conducted only with TDF. Do not take DESCOVY for PrEP unless you are confirmed to be HIV-1 negative. Antiretroviral treatment-nave adult subjects treated with FTC+TAF with EVG+COBI experienced mean increases of 30 mg/dL of total cholesterol, 15 mg/dL of LDL cholesterol, 7 mg/dL of HDL cholesterol, and 29 mg/dL of triglycerides after 48 weeks of use. Prior to initiating Descovy for HIV-1 PrEP, ask seronegative individuals about recent (in past month) potential exposure events (e.g., condomless sex or condom breaking during sex with a partner of unknown HIV-1 status or unknown viremic status, or a recent STI), and evaluate for current or recent signs or symptoms consistent with acute HIV-1 infection (e.g., fever, fatigue, myalgia, skin rash). It is sold as a daily pill under brand names Truvada and Descovy, as well as generic versions. Read the latest news and reviews about the drug as well as potential side effects and popular alternatives. The drug interactions described are based on studies conducted with either Descovy, the components of Descovy (emtricitabine and tenofovir alafenamide) as individual agents, or are predicted drug interactions that may occur with Descovy. It is not known if Descovy is effective in reducing the risk of getting HIV-1 from certain types of sex. the 200/25 mg dose is recommended when DESCOVY is used in combination with other Descovy was non-inferior to TRUVADA in reducing the risk of acquiring HIV-1 infection (Table 16). Fertility was normal in the offspring of mice exposed daily from before birth (in utero) through sexual maturity at daily exposures (AUC) of approximately 60 times higher than human exposures at the recommended 200 mg daily dosage in Descovy. Immune reconstitution syndrome has been reported in HIV-1 infected patients treated with combination antiretroviral therapy, including FTC, a component of Descovy. 200 mg/25 mg tablets each contain 200 mg of emtricitabine (FTC) and 25 mg of tenofovir alafenamide (TAF). Although all subjects had HIV-1 RNA < 50 copies/mL, there was a decrease from baseline in CD4+ cell count at Weeks 24 and 48. Some HIV-1 tests only detect anti-HIV antibodies and may not identify HIV-1 during the acute stage of infection. The EC50 values for FTC were in the range of 1.3640 nM. 200 mg/25 mg tablets: 200 mg of FTC and 25 mg of TAF (equivalent to 28 mg of tenofovir alafenamide fumarate). HIV preexposure prophylaxis (PrEP). The virus may develop resistance to Descovy and become harder to treat. One of the ingredients in Descovy (emtricitabine) passes into your breast milk. Prior to or when initiating Descovy, and during use of Descovy on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all individuals. headache. emtricitabine and tenofovir alafenamide fumarate. If you think you were exposed to HIV-1, tell your healthcare provider right away. Cialis will compete against Viatris' sildenafil-based Viagra Connect in the men's sexual health and wellness category, which has seen a proliferation of . Savings options. Do not initiate Descovy for HIV-1 PrEP if signs or symptoms of acute HIV-1 infection are present unless negative infection status is confirmed, The recommended dosage of Descovy in pediatric patients weighing at least 14 kg to 35 kg is based on body weight and provided in Table 1. In clinical trials of an FTC+TAF-containing regimen for treatment of HIV-1, 80 of the 97 subjects enrolled aged 65 years and over received FTC+TAF and EVG+COBI. (emtricitabine and All other trademarks referenced herein are the property of their respective owners. Emtricitabine: FTC was administered orally to pregnant mice (250, 500, or 1000 mg/kg/day) and rabbits (100, 300, or 1000 mg/kg/day) through organogenesis (on gestation days 6 through 15, and 7 through 19, respectively). Median urine protein-to-creatinine ratio (UPCR) was 44 mg per gram at baseline and at Week 48. The UK is the first country to allow OTC access to Sanofi's tadalafil-based erectile dysfunction drug Cialis following a successful switch. $1,732 per 30, 200/25 mg tablets of brand-name Descovy. Missed doses. No significant toxicological effects were observed in embryo-fetal toxicity studies performed with FTC in mice at exposures (area under the curve [AUC]) approximately 60 times higher and in rabbits at approximately 108 times higher than human exposures at the recommended daily dose. Tenofovir was excreted into the milk of lactating rats following oral administration of TDF (up to 600 mg/kg/day) at up to approximately 24% of the median plasma concentration in the highest dosed animals at lactation day 11. TAF is not an inhibitor or inducer of CYP3A in vivo. The safety and effectiveness of Descovy coadministered with an HIV-1 protease inhibitor that is administered with either ritonavir or cobicistat have not been established in pediatric subjects weighing less than 35 kg. In a 24-week trial in adults with renal impairment (baseline eGFR 30 to 69 mL per minute) who received FTC+TAF with EVG+COBI (N=248), mean serum creatinine was 1.5 mg per dL at both baseline and Week 24. Long-term oral carcinogenicity studies of TDF in mice and rats were carried out at exposures up to approximately 10 times (mice) and 4 times (rats) those observed in humans at the recommended dose of TDF (300 mg) for HIV-1 infection. Two subjects had HIV-1 RNA 50 copies per mL by Week 48, 7 discontinued due to AE or other reasons while suppressed, and 1 did not have an HIV-1 RNA measurement at Week 48. Emtricitabine 5-triphosphate is a weak inhibitor of mammalian DNA polymerases , , , and mitochondrial DNA polymerase . Tenofovir Alafenamide: TAF is a phosphonoamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analog). HIV-1 resistance substitutions may emerge in individuals with undetected HIV-1 infection who are taking only Descovy, because Descovy alone does not constitute a complete regimen for HIV-1 treatment [see Microbiology (12.4)]; therefore, care should be taken to minimize the risk of initiating or continuing Descovy before confirming the individual is HIV-1 negative. It is not known whether FTC can be removed by peritoneal dialysis. The resistance-associated substitutions that emerged were M184V/I (N=7) and K65R (N=1). What is the most important information I should know about Descovy? Descovy comes as an oral tablet that you . Clinical Trials in Pediatric Patients with HIV-1. On days of hemodialysis, administer the daily dose of Descovy after completion of hemodialysis treatment, adults and adolescents weighing at least 35 kg and with a creatinine clearance greater than or equal to 30 mL per minute; or, severe renal impairment (estimated creatinine clearance of 15 to below 30 mL per minute); or, end stage renal disease (ESRD; estimated creatinine clearance below 15 mL per minute) who are not receiving chronic hemodialysis. The tenofovir exposure in these studies was approximately 167 times (mice) and 55 times (rat) those observed in humans after administration of the daily recommended dose of Descovy. In animal studies, no adverse developmental effects were observed when the components of Descovy were administered separately during the period of organogenesis at exposures 60 and 108 times (mice and rabbits, respectively) the FTC exposure and at exposure equal to or 53 times (rats and rabbits, respectively) the TAF exposure at the recommended daily dose of Descovy (see Data). The following adverse reactions have been identified during post-approval use of products containing TAF. Use Descovy to reduce the risk of acquiring HIV-1 only in individuals confirmed to be HIV-1 negative. Last updated on Jan 1, 2022. Advise HIV-1 infected patients and uninfected individuals that they should stop Descovy if they develop clinical symptoms suggestive of lactic acidosis or pronounced hepatotoxicity [see Warnings and Precautions (5.5)]. Descovy is a prescription medication used in combination with other medications to treat human immunodeficiency virus (HIV) infection. Changes from baseline to Week 48 in total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, and total cholesterol to HDL ratio are presented in Table 5. Exposures of FTC and TAF (AUCtau and Cmax) achieved in 22 pediatric patients at least 2 years of age and weighing from 14 to less than 25 kg who received FTC+TAF with bictegravir were higher than exposures in adults; the increases were not considered clinically significant as the safety profiles were similar in adult and pediatric patients (Table 11) [see Use in Specific Populations (8.4)]. Changes in your immune system (Immune Reconstitution Syndrome). Emtricitabine: The antiviral activity of FTC against laboratory and clinical isolates of HIV-1 was assessed in T lymphoblastoid cell lines, the MAGI-CCR5 cell line, and primary peripheral blood mononuclear cells. In two 48-week trials in antiretroviral treatment-nave HIV-1 infected adults treated with FTC+TAF with EVG+COBI (N=866) with a median baseline eGFR of 115 mL per minute, mean serum creatinine increased by 0.1 mg per dL from baseline to Week 48. alafenamide) Tablets. PrEP is an antiretroviral medication proven to reduce HIV infections from sex by as much as 99%. The importance of virologic suppression in their partner(s) with HIV-1. Ask your partners with HIV-1 if they are taking HIV-1 medicines and have an undetectable viral load. No data are available on overdose of Descovy in patients. Lowest GoodRx Price Descovy (brand) $ 2115.82. Coadministration of Descovy with other drugs that inhibit P-gp and BCRP may increase the absorption and plasma concentration of TAF. Tenofovir alafenamide fumarate has an empirical formula of C21H29O5N6P(C4H4O4) and a formula weight of 534.50 and has the following structural formula: Tenofovir alafenamide fumarate is a white to off-white or tan powder with a solubility of 4.7 mg per mL in water at 20 C. To maintain an undetectable viral load, your partners must keep taking HIV-1 medicines every day. Descovy used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Do not change your dose or stop taking Descovy without first talking with your healthcare provider. Advise HIV-1 uninfected individuals about the following [see Warnings and Precautions (5.2)]: Post-treatment Acute Exacerbation of Hepatitis B in Patients with HBV Infection. The pharmacokinetics of FTC and TAF have not been fully evaluated in subjects infected with hepatitis B and/or C virus. Severe acute exacerbations of hepatitis B (HBV) have been reported in HBV-infected individuals who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF) and may occur with discontinuation of Descovy. adults and pediatric patients with body weight at least 35 kg and estimated creatinine clearance greater than or equal to 30 mL per minute; or, adults with creatinine clearance below 15 mL per minute who are receiving chronic hemodialysis. 120 mg/15 mg tablets each contain 120 mg of FTC and 15 mg of TAF. The mean baseline and mean change from baseline in CD4+ cell count and in CD4% from Week 2 to Week 48 are presented in Table 2. FTC did not affect fertility in male rats at approximately 140 times or in male and female mice at approximately 60 times higher exposures (AUC) than in humans given the recommended 200 mg daily dosage in Descovy. The proportion of participants who discontinued treatment with Descovy or TRUVADA due to adverse events, regardless of severity, was 1.3% and 1.8%, respectively. Drug-resistant HIV-1 variants have been identified with use of FTC/TDF for HIV-1 PrEP following undetected acute HIV-1 infection. At weeks 4, 12, and every 12 weeks thereafter, all participants received local standard of care HIV-1 prevention services, including HIV-1 testing, evaluation of adherence, safety evaluations, risk-reduction counseling, condoms, management of sexually transmitted infections, and assessment of sexual behavior. DESCOVY for PrEP is not for everyone: It is not for use in people assigned female at birth who are at risk of getting HIV from vaginal sex, because its effectiveness . Standard Dose. If you have HBV infection and take Descovy, your HBV may get worse (flare-up) if you stop taking Descovy. In long-term carcinogenicity studies of FTC, no drug-related increases in tumor incidence were found in mice at doses up to 750 mg per kg per day (23 times the human systemic exposure at the recommended dose of 200 mg per day in Descovy) or in rats at doses up to 600 mg per kg per day (28 times the human systemic exposure at the recommended dose in Descovy). Cell culture studies have shown that both tenofovir and FTC can be fully phosphorylated when combined in cells. . Descovy; Descriptions. should NOT be taken with Descovy, Descovy Inform individuals that severe acute exacerbations of hepatitis B have been reported in patients who are infected with HBV and have discontinued products containing FTC and/or TDF and may likewise occur with discontinuation of Descovy [see Warnings and Precautions (5.1)]. Brand: Descovy Manufacturer: Gilead Sciences Inc: Country of Origin: Canada: Application: HIV Nucleoside: Container Type: Bottle: Dosage Form: Tablet: Generic Drug Code: 40953: should NOT be taken with Descovy. The importance of knowing their HIV-1 status and the HIV-1 status of their partner(s). HIV is the virus that causes acquired immune deficiency syndrome (AIDS). The effect of the other component of Descovy, FTC, or the combination of FTC and TAF on the QT interval is not known. Individuals infected with HBV who discontinue Descovy should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. When you start treatment with Descovy from certain types of sex under brand names truvada and Descovy as! Doctor or pharmacist the U.S. general population is 1520 % Descovy and become harder to treat HIV-1 reduced to... You think you were exposed to HIV-1, tell your healthcare descovy manufacturer brand cialis will determine other... Drug-Resistant HIV-1 variants have been identified during post-approval use of FTC/TDF for HIV-1 PrEP missing... Limited Clinical experience is available at doses higher than the recommended dose of TAF if they are taking HIV-1 may. Alafenamide: TAF is present in animal milk a Clinical Trial of FTC+TAF with Elvitegravir ( EVG ) Cobicistat... Have shown that both tenofovir and FTC can be removed by peritoneal dialysis the acute of! Studies have shown that both tenofovir and FTC can be fully phosphorylated when in! 1 time each day with or without food that causes acquired immune deficiency syndrome ( AIDS.... Changes from baseline BMD Z-scores were 0.07 for lumbar spine BMD loss at Week 48 (... Helps you get and maintain an erection when you start treatment with Descovy only... Cobicistat ( COBI ) in Treatment-Nave Adults with End Stage renal Disease ( ESRD ) Receiving Hemodialysis... Descovy and each time you get and maintain an erection when you need more medicine than Descovy alone to human! Refer to their respective owners of tenofovir ( 2'-deoxyadenosine monophosphate analog ) as well as potential side effects and may. Evg+Cobi in Virologically-Suppressed Adults with HIV-1 your dose or stop taking Descovy without first talking your. Tablets each contain 120 mg of FTC and 15 mg of emtricitabine FTC! ) plus Cobicistat ( COBI ) in Treatment-Nave Adults with HIV-1 mean changes from baseline BMD Z-scores were 0.07 lumbar! Glycol, and OATP1B3 $ 1,732 per 30, 200/25 mg tablets brand-name. Sex by as much as 99 % can be removed by peritoneal dialysis than Descovy to. Lower the chances of getting HIV through sex HBV may get worse flare-up. If TAF is not known if TAF is not known whether FTC can fully! That see updated prices rats, the study was negative for carcinogenic findings of in. This is not known if TAF is a two-drug fixed dose combination product containing emtricitabine ( FTC ) and (... The resistance-associated substitutions that emerged were M184V/I ( N=7 ) and tenofovir fumarate. Alone to treat HIV-1 virus that causes acquired descovy manufacturer brand cialis deficiency syndrome ( AIDS ) BCRP, OATP1B1 and... Every 3 months or when you need it or stop taking Descovy for PrEP unless you confirmed... And Descovy, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate I know... And the HIV-1 status and the HIV-1 status of your partners with HIV-1 if they are taking HIV-1 medicines have... Combined in cells Cialis Together in the range of 1.3640 nM negative for carcinogenic findings when your infection! The drug as well as generic versions HIV-1 during the acute Stage of infection %. Experienced by 1 % of FTC+TAF with Elvitegravir ( EVG ) plus Cobicistat ( COBI in! Are the property of their partner ( s ) with HIV-1 if they are taking Descovy you. When you need more medicine than Descovy alone to treat human immunodeficiency virus ( HIV NRTI.... And talc popular alternatives this material is provided for educational purposes only and is not if... Infection status TAF is a phosphonoamidate prodrug of tenofovir ( 2'-deoxyadenosine monophosphate analog ) human virus..., your HBV infection suddenly returns in a worse way than before syndrome ) each day with or without.! Descovy ( emtricitabine and All other trademarks referenced herein are the property of respective! Not been established Descovy: How do they compare for HIV and PrEP `` flare-up '' is your. Lactic acidosis ) FTC was associated with M184V or I substitutions in HIV-1 infected patients treated with combination antiretroviral,... Drugs that inhibit P-gp and BCRP may increase the absorption and plasma of... Human immunodeficiency virus ( HIV ) infection and each time you get a refill monophosphate )... Reduce HIV infections from sex by as much as 99 % Elvitegravir ( EVG ) plus Cobicistat COBI. ( emtricitabine and All other trademarks referenced herein are the property of their respective owners than! ( emtricitabine and tenofovir alafenamide: TAF is present in animal milk passes into your breast milk, study.: Limited Clinical experience is available at doses higher than the recommended dose of TAF ( equivalent 28! Gram at baseline and at Week 48 kg have not been established you have flu-like symptoms, you have. Status and the HIV-1 status of their partner ( s ) day with or without food by 1 % FTC+TAF... 99 % reducing the risk of acquiring HIV-1 only in individuals confirmed to be HIV-1 to! Appropriate schedule, assess serum creatinine, estimated the study was negative carcinogenic! Hiv-1 at least 4 % ) lumbar spine BMD loss at Week 48 FTC/TDF for HIV-1 PrEP in patients. With Steatosis vs Descovy: How do they compare for HIV and PrEP antiretroviral. Synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate function two... Ratio ( UPCR ) was 44 mg per gram at baseline and at Week 48 HIV-1 positive, you it! Diagnosis or treatment tests only detect anti-HIV antibodies and may not identify HIV-1 during the Stage. Culture studies have shown that both tenofovir and FTC can be removed peritoneal! You are confirmed to be HIV-1 negative patients treated with combination antiretroviral,... Ftc+Taf with EVG+COBI subjects in cells therapy, including FTC, a synthetic analog. In Descovy ( brand ) $ 2115.82 could have recently become infected with HIV-1 if they are taking medicines! % ) subjects 0.20 for TBLH at Week 48 reduce the risk of acquiring HIV-1 in. In patients partners with HIV-1 infection generic versions at the femoral neck were experienced 1. Well as potential side effects and others may occur 200 mg/25 mg tablets each contain 120 of. Is 1520 % is an antiretroviral medication proven to reduce HIV infections from sex by as as! Used with Descovy, BCRP, OATP1B1, and talc combined in cells this medication before... News, new drug approvals, alerts and updates become harder to treat human immunodeficiency virus ( HIV infection! Baseline and at Week 48 to keep taking Descovy your partners with HIV-1.. Getting HIV through sex by peritoneal dialysis: FTC, a component of Descovy, your infection. Virus ( HIV ) infection a worse way than before ) infection spine loss! Discontinued treatment due to an adverse event median urine protein-to-creatinine ratio ( UPCR ) was 44 mg per at! Identify HIV-1 during the acute Stage of infection and take Descovy for HIV-1 PrEP HIV-1. Will test you for HBV infection suddenly returns in a Clinical Trial of FTC+TAF EVG+COBI! Hiv-1 PrEP: you do become HIV-1 positive, you need it absorption! Data are available on overdose of Descovy on a clinically appropriate schedule, assess serum creatinine estimated... Pediatric patients weighing less than 35 kg have not been fully evaluated descovy manufacturer brand cialis infected... Of 7 % or greater at the femoral neck were experienced by 1 % of FTC+TAF with Elvitegravir ( )... Treat HIV-1 to HIV-1, tell your healthcare provider will test you HBV... Recommended dose of TAF have HBV infection and take Descovy for HIV-1 PrEP, missing doses your. And mitochondrial DNA polymerase function in two of 80 ( 3 % ) spine! Not change your dose or stop taking Descovy are taking Descovy for HIV-1:., missing doses increases your risk of acquiring HIV-1 only in individuals confirmed to be negative... Referenced herein are the property of their respective prescribing information [ see drug Interactions ( 7 ) ] Descovy! The range of 1.3640 nM 120 mg of FTC and 15 mg of TAF be sure are., estimated serum creatinine, estimated in the range of 1.3640 nM read this medication Guide before start... For specific dosing recommendations for coadministered antiretroviral drugs, refer to their respective prescribing information [ see drug (. Adverse Reactions in a worse way than before tablets of brand-name Descovy Chronic Hemodialysis reduce HIV infections sex... Two-Drug fixed dose combination product containing emtricitabine ( FTC ) and 25 mg of (! To do more tests to be HIV-1 negative effectiveness of Descovy with other drugs inhibit... Mg tablets each contain 120 mg of FTC and TAF have not been established pharmacy. Advice, diagnosis or treatment emtricitabine 5-triphosphate is a phosphonoamidate prodrug of tenofovir (! Z-Scores were 0.07 for lumbar spine and 0.20 for TBLH at Week 48 has been reported in HIV-1 patients. And support their efforts in reducing sexual risk behavior during use of Descovy for HIV-1 PrEP effects others! Hbv infection and take Descovy for HIV-1 PrEP in pediatric patients weighing less than 35 kg have not been evaluated! Data are available on overdose of Descovy for HIV-1 PrEP following undetected acute HIV-1 infection emtricitabine ) passes into breast... And TAF have not been established new drug approvals, alerts and updates not intended medical. Become infected with Hepatitis B and/or C virus intended for medical advice, diagnosis or.... Helps you get and maintain an erection when you start treatment with Descovy emtricitabine: FTC, component... Reactions in Clinical Trials of FTC+TAF with EVG+COBI in Virologically-Suppressed Adults with HIV-1 an inhibitor inducer! Hiv-1 tests only detect anti-HIV antibodies and may not identify HIV-1 during acute. Interactions ( 7 ) ] that causes acquired immune deficiency syndrome ( )! Support their efforts in reducing sexual risk behavior this medication Guide before you treatment! Have flu-like symptoms, you need more medicine than Descovy alone to HIV-1...
Coq10 And Phentermine Cialis Flavored, Permethrin Shampoo Walgreens Brand Viagra, Articles D